These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

892 related items for PubMed ID: 22122182

  • 1. Striking a balance between the risks and benefits of anticoagulation bridge therapy in patients with atrial fibrillation: clinical updates and remaining controversies.
    Garwood CL, Hwang JM, Moser LR.
    Pharmacotherapy; 2011 Dec; 31(12):1208-20. PubMed ID: 22122182
    [Abstract] [Full Text] [Related]

  • 2. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW, Barillari G.
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [Abstract] [Full Text] [Related]

  • 3. Atrial fibrillation and dabigatran: has the time come to use new anticoagulants?
    Escobar C, Barrios V, Jimenez D.
    Cardiovasc Ther; 2010 Oct; 28(5):295-301. PubMed ID: 20718760
    [Abstract] [Full Text] [Related]

  • 4. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter.
    Cairns JA, Connolly S, McMurtry S, Stephenson M, Talajic M, CCS Atrial Fibrillation Guidelines Committee.
    Can J Cardiol; 2011 Oct; 27(1):74-90. PubMed ID: 21329865
    [Abstract] [Full Text] [Related]

  • 5. Home-monitoring of oral anticoagulation vs. dabigatran. An indirect comparison.
    Alonso-Coello P, Zhou Q, Guyatt G.
    Thromb Haemost; 2012 Oct; 108(4):647-53. PubMed ID: 22918481
    [Abstract] [Full Text] [Related]

  • 6. [Effective, safe stroke prevention with novel oral anticoagulants in patients with atrial fibrillation. Focus on dabigatran].
    Szapary L, Fehér G, Bosnyák E, Deli G, Csécsei P.
    Ideggyogy Sz; 2013 May 30; 66(5-6):165-74. PubMed ID: 23909016
    [Abstract] [Full Text] [Related]

  • 7. Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients.
    Prescrire Int; 2012 Feb 30; 21(124):33-6. PubMed ID: 22413715
    [Abstract] [Full Text] [Related]

  • 8. [Should dabigatran or vitamin K antagonists be used in prevention of stroke in patients with atrial fibrillation?].
    Calvo Romero JM.
    Rev Clin Esp; 2011 Mar 30; 211(3):142-6. PubMed ID: 21371701
    [Abstract] [Full Text] [Related]

  • 9. Advances in anticoagulation: focus on dabigatran, an oral direct thrombin inhibitor.
    Augoustides JG.
    J Cardiothorac Vasc Anesth; 2011 Dec 30; 25(6):1208-12. PubMed ID: 21982327
    [Abstract] [Full Text] [Related]

  • 10. Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population.
    Brunetti L, Chen C, White J.
    Consult Pharm; 2014 Mar 30; 29(3):169-78. PubMed ID: 24589766
    [Abstract] [Full Text] [Related]

  • 11. [Novel oral anticoagulants and atrial fibrillation in the elderly].
    Hanon O.
    Geriatr Psychol Neuropsychiatr Vieil; 2013 Dec 30; 11(1 Suppl):34-40. PubMed ID: 24463062
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Clinical studies, the interests and limits of using dabigatran in atrial fibrillation].
    Sternotte A, Douxfils J, Chatelain B, Chatelain C, Mullier F, Dogné JM, Spinewine A.
    J Pharm Belg; 2012 Mar 30; (1):8-17. PubMed ID: 22536678
    [Abstract] [Full Text] [Related]

  • 14. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen.
    Douketis JD, Johnson JA, Turpie AG.
    Arch Intern Med; 2004 Jun 28; 164(12):1319-26. PubMed ID: 15226166
    [Abstract] [Full Text] [Related]

  • 15. Benefits and risks of oral anticoagulation for stroke prevention in nonvalvular atrial fibrillation.
    Garcia DA.
    Thromb Res; 2012 Jan 28; 129(1):9-16. PubMed ID: 22018997
    [Abstract] [Full Text] [Related]

  • 16. Safety and efficacy of dabigatran compared with warfarin for patients undergoing radiofrequency catheter ablation of atrial fibrillation: a meta-analysis.
    Shurrab M, Morillo CA, Schulman S, Kansal N, Danon A, Newman D, Lashevsky I, Healey JS, Crystal E.
    Can J Cardiol; 2013 Oct 28; 29(10):1203-10. PubMed ID: 23993352
    [Abstract] [Full Text] [Related]

  • 17. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation.
    Ezekowitz MD, Wallentin L, Connolly SJ, Parekh A, Chernick MR, Pogue J, Aikens TH, Yang S, Reilly PA, Lip GY, Yusuf S, RE-LY Steering Committee and Investigators.
    Circulation; 2010 Nov 30; 122(22):2246-53. PubMed ID: 21147728
    [Abstract] [Full Text] [Related]

  • 18. The use of dabigatran immediately after atrial fibrillation ablation.
    Winkle RA, Mead RH, Engel G, Kong MH, Patrawala RA.
    J Cardiovasc Electrophysiol; 2012 Mar 30; 23(3):264-8. PubMed ID: 21955008
    [Abstract] [Full Text] [Related]

  • 19. Anticoagulation Bridge Therapy in Patients with Atrial Fibrillation: Recent Updates Providing a Rebalance of Risk and Benefit.
    Garwood CL, Korkis B, Grande D, Hanni C, Morin A, Moser LR.
    Pharmacotherapy; 2017 Jun 30; 37(6):712-724. PubMed ID: 28475278
    [Abstract] [Full Text] [Related]

  • 20. [Electrical cardioversion for non-valvular atrial fibrillation--underestimated risk for thromboembolic complications?].
    Klein HH.
    Dtsch Med Wochenschr; 2013 Jun 30; 138(24):1309-11. PubMed ID: 23737116
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.